Housey Pharmaceutical Research LAB

Southfield, MI 48076

SBIR Award Summary

Total Number of Awards 9
Total Value of Awards $4.3MM
First Award Date 09/01/03
Most Recent Award Date 09/24/15

Key Personnel

Last Name Name Awards Contact
Housey Gerard M Housey 9

9 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 09/24/15 - 08/31/16

DESCRIPTION (provided by applicant): This is a Phase I SBIR Application entitled "Novel Inhibitors of Multi-Drug-Resistant Mutants of BCR- ABL for the Treatment of Chronic Myelogenous Leukemia (CML) and Ph+ Acute Lymphocytic Leukemia (ALL)." The overall goal of this proposal is to further optimize and improve the efficacy of novel classes of com...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 09/24/15 - 09/23/16

DESCRIPTION (provided by applicant): This is a Phase I SBIR Application entitled "Isolation and Characterization of Low Molecular Weight Compounds Derived from Plant Extracts that Activate the IRS-2 Dependent Insulin Signaling Cascade." Diabetes is a growing and significant global health concern. Insulin Receptor Substrate-2 (IRS-2) is a criti...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 07/01/13 - 06/30/14

DESCRIPTION (provided by applicant): This is a Resubmission of an NIH Phase II SBIR Renewal Application directed towards developing and optimizing compounds that are capable of stimulating IRS2 foundation for the treatment of Type II diabetes. If successful, such compounds may also be useful for the treatment of a subset of patients with Type I ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 07/01/12 - 06/30/13

DESCRIPTION (provided by applicant): This is a Resubmission of an NIH Phase II SBIR Renewal Application directed towards developing and optimizing compounds that are capable of stimulating IRS2 foundation for the treatment of Type II diabetes. If successful, such compounds may also be useful for the treatment of a subset of patients with Type I ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 07/29/11 - 06/30/12

DESCRIPTION (provided by applicant): This is a Resubmission of an NIH Phase II SBIR Renewal Application directed towards developing and optimizing compounds that are capable of stimulating IRS2 foundation for the treatment of Type II diabetes. If successful, such compounds may also be useful for the treatment of a subset of patients with Type I ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 08/07/09 - 10/31/10

DESCRIPTION (provided by applicant): This is the Phase 1 application of an SBIR proposal entitled "Novel Inhibitors for the Treatment of Highly Drug Resistant Chronic Myelogenous Leukemia." The overall goal of this proposal is to test the efficacy of a class of novel small molecule scaffolds, which have been discovered and developed by HPRL, in ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 06/01/07 - 05/31/10

DESCRIPTION (provided by applicant): This is the Phase 2 application entitled "Discovery and Development of Antidiabetic Drugs." The goal is to identify new molecular entities that promote the IRS2-branch of the insulin/IGF signaling system. The NIH support will be used to identify compounds that promote IRS2 signaling in test cells. Myloid cell...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/10/06 - 05/31/07

DESCRIPTION (provided by applicant): This is the Phase 2 application entitled "Discovery and Development of Antidiabetic Drugs." The goal is to identify new molecular entities that promote the IRS2-branch of the insulin/IGF signaling system. The NIH support will be used to identify compounds that promote IRS2 signaling in test cells. Myloid cell...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/03 - 02/28/05

DESCRIPTION (provided by applicant): This Phase I SBIR application entitled "Discovery and Development of Antidiabetic Drugs," proposes to establish assay systems to identify and validate small molecules that promote the function of the insulin receptor substrate 2 (IRS2) in mammalian cells. IRS2 mediates the action of insulin and insulin-like g...